Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alison Tam

Dermatology Las Vegas, NV Doctor of Osteopathy

NPI 1053522573 CMS profile 228751

8530 W. Sunset Rd #130, Las Vegas, NV 89113

Open in the dashboard

General payments

$3,814

69 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alison Tam of Las Vegas, NV is reported in the CMS Open Payments database as having received $3,814 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $387 11
2024 General $1,227 29
2023 General $52 2
2022 General $426 5
2021 General $222 6
2020 General $153 4
2019 General $1,348 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alison Tam
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Alison Tam were reported at $387. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Alison Tam Dermatology median Middle half National median
2019 $1,348 $454 $129–$1,240 $163
2020 $153 $235 $81–$756 $114
2021 $222 $377 $108–$1,108 $132
2022 $426 $514 $143–$1,391 $149
2023 $52 $607 $159–$1,674 $160
2024 $1,227 $751 $204–$1,903 $164
2025 $387 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,252 38 payments
  2. Merz North America, Inc. $1,150 7 payments
  3. UCB, Inc. $264 2 payments
  4. Allergan Inc. $241 13 payments
  5. Dermavant Sciences, Inc. $140 1 payment
  6. Novartis Pharmaceuticals Corporation $124 1 payment
  7. Pfizer Inc. $124 1 payment
  8. Journey Medical Corporation $124 1 payment
  9. Regeneron Healthcare Solutions, Inc. $122 1 payment
  10. Janssen Biotech, Inc. $117 1 payment
  11. Other $156 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,950 39 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $864 30 payments
Products named General payments · program years 2019–2025
  1. Xeomin $1,150 7 payments
  2. RINVOQ $143 1 payment
  3. VTAMA $140 1 payment
  4. Cimzia $134 1 payment
  5. Bimzelx $130 1 payment
  6. SKYRIZI $125 1 payment
  7. COSENTYX $124 1 payment
  8. LITFULO $124 1 payment
  9. LIBTAYO $122 1 payment
  10. TREMFYA $117 1 payment
  11. Other $443 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

286

Median for Dermatology: 534

Drug cost

$4,858

Median for Dermatology: $67,151

Branded share of claims

17.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Hyclate Generic 43 $1,122
Tranexamic Acid Generic 29 $1,027
Finasteride Generic 36 $619
Metronidazole Generic 15 $528
Valacyclovir Valacyclovir Hcl Brand 23 $353
Clobetasol Propionate Generic 19 $341
Minoxidil Generic 15 $276
Fluconazole Generic 31 $257
Methylprednisolone Generic 17 $109
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 16 $85

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $143
$143 — —
VTAMA
  • Dermavant Sciences, Inc. $140
$140 — —
Bimzelx
  • UCB, Inc. $130
$130 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record